A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer responsible for batch release
Novartis Pharma GmbH
- Ulunar breezhaler - glycopyrronium bromide / indacaterol maleate
- Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide
- Ultibro breezhaler - indacaterol / glycopyrronium bromide
- Sialanar - glycopyrronium bromide
- Seebri breezhaler - glycopyrronium bromide
- Xoterna breezhaler - indacaterol / glycopyrronium bromide
Prescription drugs listed. Substance: "Glycopyrronium bromide"
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to medical prescription.
C.OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D.CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Risk Management Plan (RMP)
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
At the request of the European Medicines Agency.
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a signifcant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Obligation to conduct
The MAH shall complete, within the stated timeframe, the below measures:
Final report 5 years after launch.
outcomes (Multinational database cohort study to assess adverse
cardiovascular outcomes in association with inhaled
glycopyrronium in Europe).